PolyPid (PYPD) Expected to Announce Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.25).

PolyPid Stock Down 3.9%

Shares of NASDAQ PYPD opened at $3.65 on Monday. PolyPid has a twelve month low of $2.30 and a twelve month high of $3.93. The stock has a market cap of $58.04 million, a price-to-earnings ratio of -0.95 and a beta of 1.53. The company’s fifty day moving average is $3.46 and its 200-day moving average is $3.33.

Analyst Ratings Changes

Several research firms have weighed in on PYPD. Weiss Ratings reiterated a “sell (e+)” rating on shares of PolyPid in a report on Wednesday, October 8th. Roth Capital reaffirmed a “buy” rating on shares of PolyPid in a research report on Thursday, August 14th. Wall Street Zen cut PolyPid from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Wednesday, August 13th. Finally, Craig Hallum restated a “buy” rating and set a $13.00 target price (down from $15.00) on shares of PolyPid in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.40.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.